Stifel Nicolaus Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Stifel Nicolaus initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report published on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $45.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the company. Scotiabank began coverage on Palvella Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Jones Trading assumed coverage on shares of Palvella Therapeutics in a research report on Tuesday. They set a “buy” rating and a $45.00 target price for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. TD Cowen started coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $43.50.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $28.10 on Wednesday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $29.27. The business’s 50 day moving average price is $20.24. The company has a market cap of $315.31 million, a PE ratio of -2.32 and a beta of 0.54.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BML Capital Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth about $506,000. Frazier Life Sciences Management L.P. bought a new position in Palvella Therapeutics during the fourth quarter valued at approximately $7,847,000. Cresset Asset Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth approximately $251,000. Suvretta Capital Management LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $8,574,000. Finally, DAFNA Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at $857,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.